VICTORIA, BC, Jan. 30 /PRNewswire-FirstCall/ - Aspreva Pharmaceuticals Corporation today announced that Richard Glickman, Chairman and Chief Executive Officer will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York.
The 40 minute presentation will take place on Thursday, February 9th at 2:20 pm EST at the Grand Hyatt New York.
A live audio web cast of Mr. Glickman’s presentation will be available to all interested parties through a link posted on Aspreva’s website at www.aspreva.com in the Investors section.
About Aspreva Pharmaceuticals
Aspreva is an emerging pharmaceutical company focused on identifying, developing and, upon regulatory approval, commercializing new indications for approved drugs and late stage drug candidates for patients living with less common diseases. Aspreva’s “Indication Partnering” strategy allows its partners to maintain core brand focus while extending the benefits of their medicines to a broader patient population. Aspreva is listed on the Nasdaq National Market under the trading symbol “ASPV” and on the Toronto Stock Exchange under the trading symbol “ASV”.
For further information please contact: Sage Baker Executive Director, Corporate & Investor Affairs Aspreva Pharmaceuticals 250-744-2488 ext. 270 sbaker@aspreva.com
Aspreva Pharmaceuticals
CONTACT: Sage Baker, Executive Director, Corporate & Investor Affairs,Aspreva Pharmaceuticals, (250) 744-2488 ext. 270, sbaker@aspreva.com
